Adding immunotherapy drug to standard head and neck cancer treatment increases patient survival - News-Medical.Net

A University of Cincinnati clinical trial that added an immunotherapy drug to standard of care treatment regimens has shown increased survival rates for head and neck cancer patients with intermediate risk features.

A University of Cincinnati clinical trial that added an immunotherapy drug to standard of care treatment regimens has shown increased survival rates for head and neck cancer patients with intermediat… [+7876 chars]

full article...